PolyPid Ltd. has made significant strides with its lead candidate, D-PLEX 100, targeting surgical site infections via localized antibiotic delivery. The company reported positive Phase 3 data supported by multiple FDA expedited review designations, aiming for NDA submission in early 2026. Despite clinical progress and a robust patent portfolio, PolyPid remains pre-revenue with ongoing operating losses and limited cash reserves, necessitating further financing. Strategic partnerships such as the exclusive European license with Advanz may facilitate commercialization but execution risks remain.